No Data
No Data
GSK Says Depemokimab Results Show 54% Decrease in Severe Asthma Exacerbations
Express News | GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52...
Deutsche Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
GlaxoSmithKline's (GSK.US) 'first-in-class' antibody therapy Nucala achieves Phase 3 clinical primary endpoints.
Nucala was first approved for the treatment of severe asthma with eosinophilic phenotype in the USA in 2015.
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower
No Data